Comparison of Superdisintegrants in Orally Disintegrating Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Comparison of Superdisintegrants in Orally Disintegrating Tablets
The functionality and performance of three types of commercial superdisintegrants were evaluated in the application of orally disintegrating tablets.


Pharmaceutical Technology
Volume 34, Issue 7, pp. 54-65

References

1. P. Van Arnum, Pharm. Technol. 31 (10), 68–76 (2007).

2. FDA, Draft Guidance for Industry: Orally Disintegrating Tablets (Rockville, MD, April 2007).

3. T.K. Ghosh et al., "Quick Dissolving Oral Dosage Forms: Scientific and Regulatory Considerations from a Clinical Pharmacology and Biopharmaceuticals Perspective," in Drug Delivery to the Oral Cavity: Molecules to Market, T.K. Ghosh and W.R. Pfister, Eds. (CRC Press, New York, NY, 2005), pp. 337-356.

4. Luca Dobetti, Pharm. Technol. 25 (9) Drug Delivery Supplement, 44–50 (2001).

5. K. Deepak, Tablets and Capsules 7, 30–35 (2004).

6. W. Pfister and T.K. Ghosh, Pharm. Technol. 29 (10), 136–150 (2005).

7. B. Martineau, Drug Del. Technol. 9 (4), 36–38 (2009).

8. S.V. Sastry and J. Nyshasham, "Process Development and Scale-up of Oral Fast-dissolving Tablets," in Drug Delivery to the Oral Cavity: Molecules to Market, T.K. Ghosh and W.R. Pfister, Eds. (CRC Press, New York, 2005), pp. 311–336.

9. N. Sharma et al., Pharm. Technol. 27 (10), 10–13 (2003).

10. M.C. Meilgaard, G.V. Civille, B.T. Carr, Sensory Evaluation Techniques (CRC Press LLC, New York, NY, 3rd ed., 1999), pp. 369.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here